These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI. Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [Abstract] [Full Text] [Related]
8. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives]. Bron D, Vandenheule B, Stryckmans P. Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298 [No Abstract] [Full Text] [Related]
9. Non-Hodgkin's lymphoma in children. Results of therapy. Cáp J, Misíková Z, Foltinová A. Neoplasma; 1987 Sep; 34(6):735-44. PubMed ID: 2448663 [Abstract] [Full Text] [Related]
10. CHOP versus intensive regimens in non-Hodgkin's lymphoma. Salloum E, Levin M. N Engl J Med; 1993 Aug 19; 329(8):581; author reply 581-2. PubMed ID: 8336764 [No Abstract] [Full Text] [Related]
11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M. Srp Arh Celok Lek; 1998 Aug 19; 126(9-10):345-8. PubMed ID: 9863405 [Abstract] [Full Text] [Related]
12. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI. J Clin Oncol; 1990 Dec 19; 8(12):1951-8. PubMed ID: 1700079 [Abstract] [Full Text] [Related]
13. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V. Haematologica; 1998 Sep 19; 83(9):800-11. PubMed ID: 9825577 [Abstract] [Full Text] [Related]
14. [Chylothorax resulting from malignant non Hodgkin's lymphoma]. Ohyama S, Bando K, Hasegawa Y, Taniguti M, Shirayma H. Nihon Kokyuki Gakkai Zasshi; 1998 May 19; 36(5):473-7. PubMed ID: 9742867 [Abstract] [Full Text] [Related]
15. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A, García-Conde J, Alvarez-Carmona AM, León P, Maldonado J, Alcalá A, Zubizarreta A, Sancho-Tello R, Carbonell F, Contreras E, Besses C, Hernando A, Fontanillas M, Montserrat E. Med Clin (Barc); 1998 May 09; 110(16):601-4. PubMed ID: 9656196 [Abstract] [Full Text] [Related]
17. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP? Hehn ST, Miller TP. Curr Hematol Rep; 2004 Jan 09; 3(1):17-26. PubMed ID: 14695845 [Abstract] [Full Text] [Related]
19. [Non-Hodgkin's lymphomas. Results of alternating chemotherapy versus sequential chemotherapy]. Avilés A, Díaz-Maqueo JC, Torras V, Rodríguez L, López Vancell D. Sangre (Barc); 1990 Aug 09; 35(4):245-9. PubMed ID: 1703327 [Abstract] [Full Text] [Related]
20. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma]. Wang A, Luo Y, Wang Z. Zhonghua Zhong Liu Za Zhi; 1997 May 09; 19(3):215-7. PubMed ID: 10920901 [Abstract] [Full Text] [Related] Page: [Next] [New Search]